{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:50:41Z","timestamp":1762498241143,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.euf.2016.09.004","type":"journal-article","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T13:22:22Z","timestamp":1475932942000},"page":"430-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)"],"prefix":"10.1016","volume":"3","author":[{"given":"Jes\u00fas","family":"Garc\u00eda-Donas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Angel","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio.","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Vidal-Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Angel","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Garcia del Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Basterretxea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aranzazu","family":"Gonz\u00e1lez del Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Climent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Virizuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urbano","family":"Anido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Ortiz-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Rodriguez-Antona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"Rodriguez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2016.09.004_bib0155","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2016.09.004_bib0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00041552-200201000-00006","article-title":"Renal cancer: molecular mechanisms and newer therapeutic options","volume":"11","author":"Karumanchi","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.euf.2016.09.004_bib0165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumor suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.euf.2016.09.004_bib0170","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","article-title":"Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors","volume":"14","author":"Nickerson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2016.09.004_bib0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMe068263","article-title":"Renal-cell carcinoma\u2014molecular pathways and therapies","volume":"356","author":"Brugarolas","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.09.004_bib0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.09.004_bib0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon \u03b1 in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.09.004_bib0190","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2016.09.004_bib0195","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.euf.2016.09.004_bib0200","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cyto.b.20449","article-title":"Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer","volume":"76","author":"Goodale","year":"2009","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.euf.2016.09.004_bib0205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-007-9519-6","article-title":"Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer","volume":"107","author":"Naik","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.euf.2016.09.004_bib0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10456-009-9133-9","article-title":"Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib","volume":"12","author":"Vroling","year":"2009","journal-title":"Angiogenesis"},{"key":"10.1016\/j.euf.2016.09.004_bib0215","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/1471-2407-10-695","article-title":"Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib","volume":"10","author":"Gruenwald","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2016.09.004_bib0220","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/bjc.2011.72","article-title":"Levels of circulating CD45(dim) CD34(\u00fe) VEGFR2(\u00fe) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors","volume":"104","author":"Farace","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2016.09.004_bib0225","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cyto.a.20364","article-title":"Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas","volume":"71","author":"Rowand","year":"2007","journal-title":"Cytometry A"},{"key":"10.1016\/j.euf.2016.09.004_bib0230","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2016.09.004_bib0235","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2016.09.004_bib0240","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon \u03b1, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.09.004_bib0245","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase 3 trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2016.09.004_bib0250","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase 3 trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2016.09.004_bib0255","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomized phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2016.09.004_bib0260","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-08-0285","article-title":"Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment","volume":"68","author":"Palmowski","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.euf.2016.09.004_bib0265","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/sj.bjc.6604383","article-title":"Circulating endothelial cells in oncology: pitfalls and promises","volume":"98","author":"Strijbos","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2016.09.004_bib0270","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1158\/0008-5472.CAN-05-4003","article-title":"Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas","volume":"66","author":"Smirnov","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.euf.2016.09.004_bib0275","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1538-7836.2012.04681.x","article-title":"A new approach for rapid and reliable enumeration of circulating endothelial cells in patients","volume":"10","author":"Kraan","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.euf.2016.09.004_bib0280","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.09.004_bib0285","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-\u03b1 as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2016.09.004_bib0290","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/COC.0b013e3181f47aa4","article-title":"Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease","volume":"34","author":"Molina","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.euf.2016.09.004_bib0295","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1038\/bjc.2013.236","article-title":"Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma","volume":"108","author":"Motzer","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2016.09.004_bib0300","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2005-11-4570","article-title":"Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy","volume":"108","author":"Mancuso","year":"2006","journal-title":"Blood"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456916301419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456916301419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:46:32Z","timestamp":1762497992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456916301419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":30,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S2405456916301419"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2016.09.004","relation":{},"ISSN":["2405-4569"],"issn-type":[{"type":"print","value":"2405-4569"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2016.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}